Publication | Closed Access

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study

Neuro-oncologyCns ResponseVs StandardMedicineFlaura StudyCancer ManagementPathologyCancer TreatmentOncologyRadiation OncologyLung Cancer